Fig. 3.

(A and B) The difference in CD133 expression between anaplastic gliomas with and without IDH mutation. (A) The CD133/β-actin ratio analyzed by Western blotting was higher in patients with anaplastic gliomas without IDH mutation (IDH wt) than patients with IDH mutation (IDH mut, P = .025). (B) CD133 expression analyzed by immunohistochemistry was higher in patients with anaplastic gliomas without IDH mutation than patients with IDH mutation (P = .0014). (C) The difference in CD133 expression among different histological types of anaplastic gliomas. The CD133/β-actin ratio was compared among patients with anaplastic astrocytoma (AA; n = 40), anaplastic oligodendroglioma (AO; n = 34), and anaplastic oligoastrocytoma (AOA; n = 12); however, no differences were observed. (D) The CD133/β-actin ratio was compared among patients with AA (n = 13), AO (n = 15), and AOA (n = 1) without IDH mutation and glioblastomas without IDH mutation (n = 109 ( data modified from our previous report²¹). Glioblastomas showed significantly higher CD133 expression (P < .0001).